TBC Novo Nordisk Pharmaceuticals Pty Ltd
Product name
TBC
Accepted date
Jan-2024
Active ingredients
concizumab
Proposed indication
For use as a prophylaxis to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B (HB) or haemophilia A (HA).
Application type
C (new indication)
Publication date
Jan-2024